Science

Our focus at Regado is on a conundrum that has existed since the introduction of the first antithrombotic therapy.  Simply put, the antithrombotic conundrum that physicians face comprises the desire and need to prevent harmful clots while allowing healing clots to form and develop normally. Our initial efforts with the REG1 System (REG1)are in the area of arterial thrombosis and Percutaneous Coronary Intervention ( PCI)  which is a large and growing market.  In addition to PCI, there are myriad unmet medical needs and commercial opportunity for Regado Biosciences across all applications captured in the right hand column of the graphic.

Today, physicians use a variety of approaches to deal with the two consequences of suboptimal antithrombotic therapy- ischemia and bleeding.  In the case of dealing with unwanted ischemia, anticoagulants exemplified by heparin and bivalirudin (Angiomax®) are used.  These agents have demonstrated varying degrees of anticoagulant behavior and neither has an active control nor reversal agent.  In the case of bleeding, treatments include everything from frequent monitoring of anticoagulation levels to intense medical staff interaction, often using compression or closure devices and  in the case of major bleeding, transfusion.  Unfortunately, these approaches to address bleeding are not always effective and are expensive and disruptive to the healthcare system.